Evidence map›Paper›PMID 40019659›Full record

ArticleInterdisciplinary sciences, computational life sciences2025

MultiKD-DTA: Enhancing Drug-Target Affinity Prediction Through Multiscale Feature Extraction.

Riqian Hu, Ruiquan Ge, Guojian Deng, Jin Fan, Bowen Tang, Changmiao Wang

Abstract read
PubMed Publisher
In one paragraph

Article in Interdisciplinary sciences, computational life sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Riqian HuHangzhou Dianzi University, Hangzhou, 310018, China.
Ruiquan GeHangzhou Dianzi University, Hangzhou, 310018, China. gespring@hdu.edu.cn.ORCID http://orcid.org/0000-0001-5713-5588
Guojian DengHangzhou Dianzi University, Hangzhou, 310018, China.
Jin FanHangzhou Dianzi University, Hangzhou, 310018, China.
Bowen TangMindRank AI Ltd., Hangzhou, 310018, China.
Changmiao WangShenzhen Research Institute of Big Data, Shenzhen, 518172, China. cmwangalbert@gmail.com.

Funding

Basic and Applied Basic Research Foundation of Guangdong Province 2022A1515110570Innovation Teams of Youth Innova- tion in Science and Technology of High Education Institutions of Shandong Province 2021KJ088National Natural Science Foundation of China 61702146National Natural Science Foundation of China 62376081Open Project Program of the State Key Laboratory of CAD&CG, Zhejiang University A2410Zhejiang Provincial Natural Science Foundation of China LY21F020017
6 · The paper itself

Abstract

The discovery and development of novel pharmaceutical agents is characterized by high costs, lengthy timelines, and significant safety concerns. Traditional drug discovery involves pharmacologists manually screening drug molecules against protein targets, focusing on binding within protein cavities. However, this manual process is slow and inherently limited. Given these constraints, the use of deep learning techniques to predict drug-target interaction (DTI) affinities is both significant and promising for future applications. This paper introduces an innovative deep learning architecture designed to enhance the prediction of DTI affinities. The model ingeniously combines graph neural networks, pre-trained large-scale protein models, and attention mechanisms to improve performance. In this framework, molecular structures are represented as graphs and processed through graph neural networks and multiscale convolutional networks to facilitate feature extraction. Simultaneously, protein sequences are encoded using pre-trained ESM-2 large models and processed with bidirectional long short-term memory networks. Subsequently, the molecular and protein embeddings derived from these processes are integrated within a fusion module to compute affinity scores. Experimental results demonstrate that our proposed model outperforms existing methods on two publicly available datasets.

Indexed as

Deep LearningDrug DiscoveryProteinsHumansNeural Networks, ComputerProteinsDrug-target interactionEvolutionary scale modelingGraph neural networkMultiscale convolutional neural network

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.